Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of EGETIS THERAPEUTICSCS AB
No Price
Closing Price XSTO 28.04.2026:
5,79 SEK
28.04.2026 15:29
Current Prices from EGETIS THERAPEUTICSCS AB
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
NASDAQ STOCKHOLM AB
EGTX.ST
SEK
28.04.2026 15:29
5,79 SEK
-0,12 SEK
-2,03 %
Share Float & Liquidity
Free Float55,48 %
Shares Float219,23 M
Shares Outstanding395,16 M
Company Profile for EGETIS THERAPEUTICSCS AB Share
Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.
